![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0025.png)
allied
academies
Page 58
Notes:
Journal of Nutrition and Human Health | Volume 3
May 23-24, 2019 | Vienna, Austria
Joint Event
2
nd
International Conference on
Gastroenterology and Digestive Disor
ders
17
th
International Conference on
Nutrition and Fitness
&
Prevalence of lamivudine drug resistance among hepatitis B virus untreated patients
Milud Ahmed Salem
1,2
, Fatie Moftah Alfazzani
3
and
Elfatah M Elnifro
2,4
1
Gharyan University, Libya
2
Saint Jamis Hospital, Libya
3
Higher Institute of Science and Technology, Libya
4
University of Al-Marghib, Libya
Background:
Hepatitis B virus (HBV) represents a global
health challenge due to its worldwide distribution and
serious complications. Mutations of HBV polymerase,
especially occurring at the highly conserved YMDD region,
are related to resistance to lamivudine. Although these
mutations are frequently secondary to lamivudine use,
they can also occur naturally.
Aim:
The aim of this study is to determine the prevalence
of genotypic resistance to lamivudine in HBV isolates
obtained from untreated HBV-infected individuals.
Methods:
Quantitative real-time PCR assay was carried out
on One hundred and fifteen clinical specimens of chronic
carriers. The specimens were extracted and amplified
using INNO-LiPA HBV Drug Resistance primers and run on
a 2% agarose gel, YMDD variants were analyzed by the HBV
Drug Resistance Line Probe assay (Inno-Lipa HBV-DR).
Results:
YMDD variants were detected in 40 (70.1%) of the
57 inactive HBV carriers. The YIDD mutant was presented
in all cases (40 cases), either alone or associated with
YVDD or V80+I80.
Conclusion:
HBV genotypic resistance to lamivudine in
untreated HBV-infected is common.
e
:
milud.salem@jgu.edu.ly